vunakizumab and recaticimab.

ApprovedMonoclonal antibody

XXiangya Hospital of Central South University

vunakizumab and recaticimab. is one of 31 small molecule programs targeting Psoriasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

PsoriasisApproved

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Preclinical

37 2

vunakizumab and recaticimab.

XXiangya Hospital of Central South University

Approved

1 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Psoriasis

NCT07373847

Clinical

Trials by Indication[1]

Psoriasis1 trial

Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

Not yet recruiting·XXiangya Hospital of Central South University·Phase 4·NCT07373847·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for vunakizumab and recaticimab.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vunakizumab and recaticimab. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vunakizumab and recaticimab.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: XXiangya Hospital of Central South University

vunakizumab and recaticimab.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News